|
US5262564A
(en)
|
1992-10-30 |
1993-11-16 |
Octamer, Inc. |
Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
|
|
ATE278674T1
(de)
|
1999-03-12 |
2004-10-15 |
Boehringer Ingelheim Pharma |
Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
|
|
EP1690854A1
(en)
|
1999-03-12 |
2006-08-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic urea and related compounds useful as anti-inflammatory agents
|
|
EP1466906A1
(en)
|
1999-03-12 |
2004-10-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic urea and related compounds useful as anti-inflammatory agents
|
|
HU230030B1
(hu)
|
1999-10-08 |
2015-05-28 |
Debiopharm International Sa |
Fab I inhibitorok
|
|
US6703525B2
(en)
|
2000-02-16 |
2004-03-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Sulfonamide intermediates and methods of producing same
|
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
|
EP1560584B1
(en)
|
2001-04-06 |
2009-01-14 |
Affinium Pharmaceuticals, Inc. |
Fab i inhibitors
|
|
WO2002083642A1
(en)
|
2001-04-13 |
2002-10-24 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
|
WO2003022273A1
(en)
|
2001-09-13 |
2003-03-20 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediated diseases
|
|
JP4303109B2
(ja)
|
2001-10-04 |
2009-07-29 |
メルク エンド カムパニー インコーポレーテッド |
代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤
|
|
US20050101518A1
(en)
|
2002-01-18 |
2005-05-12 |
David Solow-Cordero |
Methods of treating conditions associated with an EDG-2 receptor
|
|
MXPA04005939A
(es)
|
2002-01-22 |
2005-01-25 |
Warner Lambert Co |
2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
|
|
WO2003062234A1
(en)
|
2002-01-23 |
2003-07-31 |
Yamanouchi Pharmaceutical Co., Ltd. |
Quinoxaline compounds
|
|
US20040023961A1
(en)
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
|
AU2003218462A1
(en)
|
2002-10-01 |
2004-04-23 |
Merck And Co., Inc. |
Treatment of obesity and other disorders associated with excessive food intake
|
|
WO2004082586A2
(en)
|
2003-03-17 |
2004-09-30 |
Affinium Pharmaceuticals, Inc. |
Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
|
|
CA2536293A1
(en)
|
2003-08-22 |
2005-03-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating copd and pulmonary hypertension
|
|
JP2007504229A
(ja)
*
|
2003-09-02 |
2007-03-01 |
メルク エンド カムパニー インコーポレーテッド |
代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
|
|
WO2005023761A2
(en)
|
2003-09-11 |
2005-03-17 |
Kemia, Inc. |
Cytokine inhibitors
|
|
MX2007001550A
(es)
|
2004-08-09 |
2007-04-10 |
Astellas Pharma Inc |
Compuestos de hidroxiamida que tienen actividad como inhibidores de histona desacetilasa (hdac).
|
|
MX2008003172A
(es)
|
2005-09-06 |
2008-03-18 |
Smithkline Beecham Corp |
Proceso regioselectivo para la preparacion de bencimidazol-tiofenos.
|
|
US20080214563A1
(en)
|
2005-09-06 |
2008-09-04 |
Mui Cheung |
Benzimidazole Thiophene Compounds As Plk Modulators
|
|
WO2007056075A2
(en)
|
2005-11-02 |
2007-05-18 |
Targegen, Inc. |
Six membered heteroaromatic inhibitors targeting resistant kinase mutations
|
|
WO2007058990A2
(en)
|
2005-11-14 |
2007-05-24 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
|
RU2426731C2
(ru)
|
2005-12-23 |
2011-08-20 |
Ф. Хоффманн-Ля Рош Аг |
Производные арил-изоксазоло-4-ил-оксадиазола
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
CA2641579A1
(en)
|
2006-02-07 |
2007-08-16 |
Astellas Pharma Inc. |
N-hydroxyacrylamide compounds
|
|
CN101384586A
(zh)
*
|
2006-02-14 |
2009-03-11 |
诺华公司 |
Pi-3激酶抑制剂及其应用方法
|
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
|
US7855194B2
(en)
|
2006-03-27 |
2010-12-21 |
Hoffmann-La Roche Inc. |
Pyrimidine, quinazoline, pteridine and triazine derivatives
|
|
EP2032563B1
(en)
|
2006-06-02 |
2010-06-02 |
GlaxoSmithKline LLC |
Benzimidazol substituted thiophene derivatives with activity on plk
|
|
US7615643B2
(en)
|
2006-06-02 |
2009-11-10 |
Smithkline Beecham Corporation |
Benzimidazole thiophene compounds
|
|
CA2691214A1
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
|
DE102007007751A1
(de)
|
2007-02-16 |
2008-08-21 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
AR067326A1
(es)
|
2007-05-11 |
2009-10-07 |
Novartis Ag |
Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
|
|
DE102007035333A1
(de)
|
2007-07-27 |
2009-01-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
GB0719644D0
(en)
|
2007-10-05 |
2007-11-14 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
GB0720444D0
(en)
|
2007-10-18 |
2007-11-28 |
Glaxo Group Ltd |
Novel compounds
|
|
EA201001030A1
(ru)
|
2007-12-19 |
2011-02-28 |
Амген Инк. |
Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
|
|
US7683064B2
(en)
|
2008-02-05 |
2010-03-23 |
Roche Palo Alto Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
US20100029657A1
(en)
|
2008-02-29 |
2010-02-04 |
Wyeth |
Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
|
|
PH12012502374A1
(en)
|
2008-06-24 |
2014-11-12 |
Hoffmann La Roche |
Novel substituted pyridin-2-ones and pyridazin-3-ones
|
|
US8445505B2
(en)
|
2008-06-25 |
2013-05-21 |
Irm Llc |
Pyrimidine derivatives as kinase inhibitors
|
|
AU2009262198B2
(en)
|
2008-06-25 |
2012-09-27 |
Irm Llc |
Pyrimidine derivatives as kinase inhibitors
|
|
EP2321309A1
(en)
|
2008-06-25 |
2011-05-18 |
Ranbaxy Laboratories Limited |
Benzothiazoles and aza-analogues thereof use as antibacterial agents
|
|
CA2729045A1
(en)
|
2008-07-31 |
2010-02-04 |
Philippe Bergeron |
Pyrimidine compounds, compositions and methods of use
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
US20110172217A1
(en)
|
2008-09-05 |
2011-07-14 |
Shionogi & Co., Ltd. |
Ring-fused morpholine derivative having pi3k-inhibiting activity
|
|
GB0821307D0
(en)
|
2008-11-21 |
2008-12-31 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
|
US20120040916A1
(en)
|
2008-12-22 |
2012-02-16 |
Massachusetts Institute Of Technology |
Molecular inhibitors of the wnt/beta-catenin pathway
|
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
US8299077B2
(en)
|
2009-03-02 |
2012-10-30 |
Roche Palo Alto Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
BRPI1014821A2
(pt)
|
2009-04-09 |
2016-04-05 |
Boehringer Ingelheim Int |
"inibidores de replicação de hiv"
|
|
AU2010255727B2
(en)
|
2009-06-04 |
2013-02-28 |
Novartis Ag |
1H-imidazo[4,5-c]quinolinone derivatives
|
|
JP2012529512A
(ja)
|
2009-06-08 |
2012-11-22 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
トリアジン誘導体類及びそれらの治療応用
|
|
MX2012001974A
(es)
|
2009-08-19 |
2012-04-11 |
Ambit Biosciences Corp |
Compuestos de biarilo y metodos de uso de los mismos.
|
|
WO2011021678A1
(ja)
|
2009-08-21 |
2011-02-24 |
武田薬品工業株式会社 |
縮合複素環化合物
|
|
US8759332B2
(en)
|
2009-09-11 |
2014-06-24 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
|
WO2011031934A1
(en)
|
2009-09-11 |
2011-03-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
US8927709B2
(en)
|
2009-09-11 |
2015-01-06 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
|
US8703938B2
(en)
|
2009-09-11 |
2014-04-22 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
|
US8815928B2
(en)
|
2009-09-11 |
2014-08-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
|
US8822700B2
(en)
|
2009-09-11 |
2014-09-02 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
|
WO2011090738A2
(en)
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
EP2558092B1
(en)
|
2010-04-13 |
2018-06-27 |
Novartis AG |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
|
PT2616465E
(pt)
|
2010-09-13 |
2016-03-09 |
Novartis Ag |
Triazino-oxadiazoles
|
|
EP2625178A4
(en)
|
2010-10-08 |
2014-04-30 |
Biota Europe Ltd |
BACTERIA TOPOISOMERASE II FOR INHIBITING 2-ETHYL CARBAMOYLAMINE-1,3-BENZOTHIAZOL-5-YLENE
|
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
|
CN102617548A
(zh)
|
2011-01-31 |
2012-08-01 |
北京赛林泰医药技术有限公司 |
作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
|
|
CN103502249A
(zh)
|
2011-05-17 |
2014-01-08 |
普林斯匹亚生物制药公司 |
作为酪氨酸激酶抑制剂的氮杂吲哚衍生物
|
|
US9216173B2
(en)
|
2011-10-05 |
2015-12-22 |
Merck Sharp & Dohme Corp. |
2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
|
|
ES2575604T3
(es)
|
2012-01-13 |
2016-06-29 |
Bristol-Myers Squibb Company |
Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa
|
|
EP2802576B1
(en)
|
2012-01-13 |
2018-06-27 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
|
CN104169275B
(zh)
|
2012-01-13 |
2017-06-09 |
百时美施贵宝公司 |
用作激酶抑制剂的三唑取代的吡啶化合物
|
|
HRP20180037T1
(hr)
*
|
2012-04-17 |
2018-03-23 |
Fujifilm Corporation |
Heterociklični spoj koji sadrži dušik ili njegovu sol
|
|
EP2863916B1
(en)
|
2012-06-22 |
2018-07-18 |
Merck Sharp & Dohme Corp. |
Substituted pyridine spleen tyrosine kinase (syk) inhibitors
|
|
US8729263B2
(en)
|
2012-08-13 |
2014-05-20 |
Novartis Ag |
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
|
|
MX2015004615A
(es)
|
2012-10-16 |
2015-07-17 |
Hoffmann La Roche |
Inhibidores de serina/treonina cinasa.
|
|
WO2014106800A2
(en)
|
2013-01-04 |
2014-07-10 |
Aurigene Discovery Technologies Limited |
Substituted 2-amino pyrimidine derivatives as kinase inhibitors
|
|
TW201443037A
(zh)
|
2013-01-09 |
2014-11-16 |
Gilead Sciences Inc |
治療用化合物
|
|
JPWO2015016206A1
(ja)
|
2013-07-30 |
2017-03-02 |
武田薬品工業株式会社 |
複素環化合物
|
|
JPWO2015098991A1
(ja)
|
2013-12-26 |
2017-03-23 |
東レ株式会社 |
Ｎ−アルキルアミド誘導体及びその医薬用途
|
|
EP3096754B1
(en)
|
2014-01-22 |
2018-08-29 |
Merck Sharp & Dohme Corp. |
Metallo-beta-lactamase inhibitors
|
|
WO2015131080A1
(en)
|
2014-02-28 |
2015-09-03 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
DK3149008T3
(en)
|
2014-05-28 |
2019-04-01 |
Shanghai Fochon Pharmaceutical Co Ltd |
Specific protein kinase inhibitors
|
|
WO2016015605A1
(en)
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
Compounds as cdk small-molecule inhibitors and uses thereof
|
|
WO2016022644A1
(en)
|
2014-08-06 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Heterocyclic cgrp receptor antagonists
|
|
EP3195866B1
(en)
|
2014-08-22 |
2020-11-18 |
FUJIFILM Corporation |
Pharmaceutical composition for treating flt3 mutation-positive cancer, mutant flt3 inhibitor and uses thereof
|
|
EP3191467B1
(en)
|
2014-09-12 |
2020-10-21 |
Novartis AG |
Compounds and compositions as kinase inhibitors
|
|
MX381224B
(es)
|
2014-10-31 |
2025-03-12 |
Massachusetts Gen Hospital |
Potentes moduladores de gamma-secretasa.
|
|
WO2016089208A2
(en)
|
2014-12-04 |
2016-06-09 |
Stichting Maastricht Radiation Oncology "Maastro-Clinic" |
Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents
|
|
EP3053577A1
(en)
|
2015-02-09 |
2016-08-10 |
F. Hoffmann-La Roche AG |
Compounds for the treatment of cancer
|
|
WO2016128343A1
(en)
|
2015-02-09 |
2016-08-18 |
F. Hoffmann-La Roche Ag |
Compounds for the treatment of cancer
|
|
TWI788655B
(zh)
|
2015-02-27 |
2023-01-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
|
SG11201707638UA
(en)
|
2015-04-14 |
2017-10-30 |
Qurient Co Ltd |
Quinoline derivatives as tam rtk inhibitors
|
|
SG11201709837RA
(en)
|
2015-05-29 |
2017-12-28 |
Teijin Pharma Ltd |
PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
|
|
JP6947651B2
(ja)
*
|
2015-06-26 |
2021-10-13 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
４，６−ピリミジニレン誘導体およびこれらの使用
|
|
US10829484B2
(en)
|
2015-07-28 |
2020-11-10 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
CN106608879A
(zh)
|
2015-10-27 |
2017-05-03 |
甘李药业股份有限公司 |
一种蛋白激酶抑制剂及其制备方法和医药用途
|
|
IL294124B2
(en)
|
2015-12-10 |
2024-02-01 |
Ptc Therapeutics Inc |
Methods for treating huntington's disease
|
|
CN108699055B
(zh)
|
2015-12-13 |
2020-10-23 |
杭州英创医药科技有限公司 |
用作抗癌药物的杂环化合物
|
|
ES2904615T3
(es)
|
2016-03-16 |
2022-04-05 |
Plexxikon Inc |
Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
|
|
EP3445765A4
(en)
|
2016-04-22 |
2019-09-18 |
Dana Farber Cancer Institute, Inc. |
DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
|
|
KR102498741B1
(ko)
|
2016-04-29 |
2023-02-10 |
에프지에이치 바이오테크 인코포레이티드 |
질환 치료용 이-치환된 피라졸 화합물
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2018045957A1
(zh)
|
2016-09-07 |
2018-03-15 |
江苏豪森药业集团有限公司 |
一种cdk4/6抑制剂及其制备方法和应用
|
|
WO2018106870A1
(en)
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|
|
EP3558991A2
(en)
|
2016-12-23 |
2019-10-30 |
Plexxikon Inc. |
Compounds and methods for cdk8 modulation and indications therefor
|
|
CN110799190B
(zh)
|
2017-03-27 |
2024-04-19 |
卡都瑞恩医药有限公司 |
杂环化合物
|
|
US12428423B2
(en)
|
2017-04-01 |
2025-09-30 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
|
|
KR20200017476A
(ko)
|
2017-06-14 |
2020-02-18 |
피티씨 테라퓨틱스, 인크. |
Rna 스플라이싱의 변경 방법
|
|
CN109516989B
(zh)
|
2017-09-17 |
2021-12-31 |
上海美志医药科技有限公司 |
一类抑制并降解cdk的化合物
|
|
IL273924B2
(en)
|
2017-10-20 |
2024-07-01 |
Univ Vanderbilt |
Antagonists of the muscarinic acetylcholine receptor m4
|
|
EP3707138B1
(en)
|
2017-11-06 |
2022-07-13 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
WO2019126559A1
(en)
|
2017-12-20 |
2019-06-27 |
Vanderbilt University |
Antagonists of the muscarinic acetylcholine receptor m4
|
|
US11919902B2
(en)
|
2017-12-22 |
2024-03-05 |
Hibercell, Inc. |
Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
|
WO2019126731A1
(en)
|
2017-12-22 |
2019-06-27 |
Petra Pharma Corporation |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
|
US11584763B2
(en)
|
2017-12-22 |
2023-02-21 |
Hibercell, Inc. |
Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
|
IL276411B2
(en)
|
2018-02-02 |
2024-04-01 |
Univ Vanderbilt |
M4 muscarinic acetylcholine receptor antagonists
|
|
JP2021514359A
(ja)
*
|
2018-02-15 |
2021-06-10 |
ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． |
キナーゼ阻害剤としての複素環式化合物
|
|
MX2020009957A
(es)
|
2018-03-27 |
2021-01-15 |
Ptc Therapeutics Inc |
Compuestos para el tratamiento de enfermedad de hungtinton.
|
|
WO2019213340A1
(en)
|
2018-05-03 |
2019-11-07 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
|
PL3814357T3
(pl)
|
2018-06-27 |
2024-09-16 |
Ptc Therapeutics, Inc. |
Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
|
|
AU2019309909A1
(en)
|
2018-07-23 |
2021-02-04 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
|
|
MX2021004191A
(es)
|
2018-10-15 |
2021-05-27 |
Nurix Therapeutics Inc |
Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
|
|
EP3877052B1
(en)
*
|
2018-11-06 |
2023-08-16 |
Edgewise Therapeutics, Inc. |
Pyridazinone compounds and uses thereof
|
|
WO2020109191A1
(en)
|
2018-11-27 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Aryl compounds for the treatment and prophylaxis of bacterial infection
|
|
CN113166105B
(zh)
|
2018-11-30 |
2024-11-08 |
杭州英创医药科技有限公司 |
作为cdk-hdac双通路抑制剂的杂环化合物
|
|
WO2020114487A1
(en)
|
2018-12-07 |
2020-06-11 |
Sunshine Lake Pharma Co., Ltd. |
Ret inhibitors, pharmaceutical compositions and uses thereof
|
|
CN113166148B
(zh)
|
2018-12-07 |
2024-04-12 |
杭州英创医药科技有限公司 |
作为cdk-hdac双通路抑制剂的杂环化合物
|
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
|
JP2022516555A
(ja)
|
2019-01-04 |
2022-02-28 |
プラクシス バイオテック エルエルシー |
線維芽細胞活性化タンパク質の阻害剤
|
|
EP3920918A4
(en)
|
2019-02-05 |
2022-11-16 |
Skyhawk Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
|
|
WO2020163544A1
(en)
|
2019-02-06 |
2020-08-13 |
Skyhawk Therapeutics, Inc. |
Methods and compositions for modulating splicing
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
CN113661164B
(zh)
|
2019-04-08 |
2025-03-04 |
珠海宇繁生物科技有限责任公司 |
一种cdk激酶抑制剂及其应用
|
|
MA55909A
(fr)
|
2019-05-05 |
2022-03-16 |
Qilu Regor Therapeutics Inc |
Inhibiteurs de cdk
|
|
WO2020231977A1
(en)
|
2019-05-13 |
2020-11-19 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
TW202112784A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|